Investment Analysts’ Weekly Ratings Changes for Definium Therapeutics (DFTX)

Definium Therapeutics (NASDAQ: DFTX) recently received a number of ratings updates from brokerages and research firms:

• 9/15/2026 – Definium Therapeutics was given a new $78.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 9/15/2026 – Definium Therapeutics had its “buy” rating reaffirmed by UBS Group AG. They now have a $70.00 price target on the stock.
• 9/15/2026 – Definium Therapeutics had its price target raised by Robert W. Baird from $75.00 to $79.00. They now have an “outperform” rating on the stock.
• 9/14/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $75.00 price target on the stock.
• 9/14/2026 – Definium Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
• 9/14/2026 – Definium Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $66.00 price target on the stock.
• 9/11/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $66.00 price target on the stock.
• 8/18/2026 – Definium Therapeutics is now covered by Bank of America Corporation. They set a “buy” rating and a $75.00 price target on the stock.
• 8/14/2026 – Definium Therapeutics was given a new $55.00 price target by Maxim Group. They now have a “buy” rating on the stock.
• 8/13/2026 – Definium Therapeutics was given a new $64.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by JonesTrading from $74.00 to $90.00. They now have a “buy” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by Royal Bank Of Canada from $57.00 to $66.00. They now have an “outperform” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by Wells Fargo & Company from $68.00 to $72.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by Robert W. Baird from $57.00 to $75.00. They now have an “outperform” rating on the stock.
• 8/12/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $70.00 price target on the stock.
• 8/12/2026 – Definium Therapeutics had its price target raised by Needham & Company LLC from $50.00 to $66.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Definium Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – Definium Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $75.00 price target on the stock, up from $73.00.
• 7/27/2026 – Definium Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.
• 7/27/2026 – Definium Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.

Insider Buying and Selling at Definium Therapeutics

In other news, CEO Robert Barrow sold 19,023 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $37.94, for a total transaction of $721,732.62. Following the completion of the transaction, the chief executive officer directly owned 1,494,640 shares in the company, valued at approximately $56,706,641.60. The trade was a 1.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.40% of the company’s stock.

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Featured Stories

• Five stocks we like better than Definium Therapeutics
• Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
• Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
• Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
• Oil May Be Stronger Than It Looks—And Diamondback Is on Sale

Receive News & Ratings for Definium Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.